An examination of the association between therapeutic anticoagulation control and glycemic control for patients with diabetes on oral anticoagulation therapy

Journal of Thrombosis and Thrombolysis

Volumn 19, Issue 3, 2005, Pages 209-212

  Johnson, Samuel G ^a   Witt, Daniel M ^a,b   Delate, Thomas ^a   Sadler, Melanie A ^a  

^a Clinical Pharmacy Services   (United States)

^b NONE   (United States)

Author keywords

Anticoagulants; Diabetes mellitus; Hemoglobin a glycosylated; Prothrombin time

Indexed keywords

ANTICOAGULANT AGENT; GLUCOSE; HEMOGLOBIN A1C; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DRUG INTERACTIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WARFARIN;

EID: 23844496714     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-1715-9     Document Type: Article

References (13)

1. Hirsch J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(Suppl):231S-246S. 7555179
2. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of Warfarin with drugs and food. Ann Int Med 1994;121:676-683. 7944078
3. American Diabetes Association Position Statement. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1998;21(Suppl 1):S32-S35.
4. Russell MW, Taylor DC, Cummins G, Huse DM. Use of managed care claims data in the risk assessment of venous thromboembolism in outpatients. Am J Manag Care 2002;8(Suppl 1):S3-9. 11822347
5. Krugluger W, Kopp HP, Schernthaner G, Hopmeier P. Enhanced response to activated Protein C in patients with IDDM. Diabetes Care 1995;44(9):1033-1037.
6. Gabazza EC, Takeya H, Deguchi H, et al. Protein C activation in NIDDM patients. Diabetologia 1996;39:1455-1461. 10.1007/s001250050598
7. Brannstrom M, Jansson JH, Boman K, Nilsson TK. Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment. Thromb Haemost 1995;74(2):612-615. 8584993
8. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BH. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes Care 1995;44:80-84.
9. Carr ME. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001;15:44-54. 10.1016/S1056-8727(00)00132-X
10. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
11. National Diabetes Education Program. If you have diabetes, know your blood sugar numbers. March 2000. Available at: http://www.ndep.nih.gov/ diabetes/pubs/KnowNumbers_Eng.pdf. Accessed February 2, 2005.
12. Hansten PD, Horn JT, ed. Drug Interactions Analysis and Management: A Clinical Perspective and Analysis of Current Developments. St. Louis: Wolters Kluwer Health. 2003,
13. American Heart Association. Anticoagulation. January 2005. Available at: http://www.americanheart.org/presenter.jhtml?identifier=11079. Accessed February 2, 2005.